



## **XBiotech to Provide Third Quarter 2016 Business Update on November 15**

November 10, 2016

AUSTIN, Texas, Nov. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIO), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast on Tuesday, November 15, 2016, at 8:30 a.m. ET, to provide a quarterly overview for the third quarter ended September 30, 2016.

### **Conference Call Information:**

Interested participants and investors may access the conference call by dialing:

- 1 (844) 249-9385 (U.S.)
- 1 (270) 823-1533 (international)
- Conference ID: 13324077

A webcast will also be accessible via the Investors Relations section of the XBiotech website [investors.xbiotech.com](http://investors.xbiotech.com). The webcast replay will remain available for 90 days.

### **About True Human™ Therapeutic Antibodies**

Unlike previous generations of antibody therapies, XBiotech's True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

### **About XBiotech**

XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit [www.xbiotech.com](http://www.xbiotech.com).

### **Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Ashley Otero

[aotero@xbiotech.com](mailto:aotero@xbiotech.com)

512.386.2930



XBiotech, Inc